

Serial No.: 09/346,069
Filed: July 1, 1999

IN THE SPECIFICATION:

Please replace the first paragraph after the heading "Cross-Reference to Related Applications" at page 1, line 4, as amended by the transmittal accompanying the present application, with the following paragraph:

C₁ Sub-D₃
This is a continuation-in-part application of application Serial No. 08/567,200 filed December 5, 1995, now Patent No. 6,020,473 which issued February 1, 2000 and a continuation-in-part of application Serial No. 08/691,794 filed August 2, 1996, now Patent No. 6,057,428 which issued May 2, 2000, and claims the benefit of provisional application No. 60/002,827 filed August 25, 1995.

At page 5, line 4, please insert the following paragraph:

C₂
In yet another embodiment of the invention, mutagenesis is effected at positions Phe 17, Ile 43 and/or Ile 46.

IN THE CLAIMS:

Please enter the following new claim set, cancelling without prejudice or disclaimer all previously pending claims not reiterate:

C₃
15. The composition of matter of Claim 18, wherein the carrier is a pharmaceutically acceptable carrier.

18. A composition of matter comprising:

C₄ Sub-D₁
a) a purified polypeptide, said polypeptide comprising a vascular endothelial cell growth factor (VEGF) variant of native VEGF wherein said variant differs from native VEGF in that said variant contains at least one modification in the Kinase domain region (KDR) and/or FMS-like Tyrosine Kinase region (FLT-1) such that the binding affinity of said region(s) is modified with respect to binding affinity of KDR and or FLT-1 receptor(s) with native VEGF; and